

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (original): A GBV-B replicon comprising the following regions:

a GBV-B 5' UTR substantially similar to bases 1-445 of SEQ ID NO 1;

a selection or reporter sequence functionally coupled to said GBV-B 5' UTR;

an internal ribosome entry site;

a NS3-NS5B sequence substantially similar to bases 1938-7709 of SEQ ID NO: 1 functionally coupled to said internal ribosome entry site and an AUG translation initiation codon; and

a GBV-B 3' UTR substantially similar to bases 7710-8069 of SEQ ID NO: 1, wherein said replicon is capable of replication in a cell.

Claim 2 (original): The GBV-B replicon of claim 1, further comprising a GBV-B structural region, wherein said GBV-B structural region is functionally coupled to said GBV-B 5' UTR.

Claim 3 (original): The GBV-B replicon of claim 2, wherein

said GBV-B structural region comprises a sequence substantially similar to a sequence selected from the group consisting of: bases 446-511 of SEQ ID NO: 1, bases 446-487 of SEQ ID NO: 1, bases of 446-469 of SEQ ID NO: 1, the RNA version of bases 446-2641 of SEQ ID NO: 2, and the RNA version of bases 446-3265 of SEQ ID NO: 2.

Claim 4 (original): The GBV-B replicon of claim 3, wherein said replicon consists of:

said GBV-B 5' UTR;

said GBV-B structural region;

said selection or reporter sequence;

said internal ribosome entry site;  
said NS3-NS5B sequence; and  
said GBV-B 3' UTR.

Claim 5 (original): The GBV-B replicon of claim 4, wherein  
said internal ribosome entry site has the sequence of bases 1324-1934 of SEQ ID  
NO 1;

said GBV-B structural region consisting of a sequence selected from the group  
consisting of: bases 446-511 of SEQ ID NO: 1, bases 446-487 of SEQ ID NO: 1, bases of 446-  
469 of SEQ ID NO 1, the RNA version of bases 446-2642 of SEQ ID NO: 2 and the RNA  
version of bases 446-3265 of SEQ ID NO: 2;

said NS3-NS5B region is Met-NS3-NS5B region consisting of bases 1935-7709  
of SEQ ID NO: 1; and

said GBV-B 3' UTR is bases 7710-8069 of SEQ ID NO: 1.

Claim 6 (original): The GBV-B replicon of claim 5, wherein said GBV-B  
structural region consists either of the RNA version of bases 446-2642 of SEQ ID NO: 2 or the  
RNA version of bases 446-3265 of SEQ ID NO: 2.

Claim 7 (original): The GBV-B replicon of claim 1, wherein said replicon  
consists of SEQ ID NO: 1.

Claim 8 (original): The GBV-B replicon of claim 2, wherein  
said GBV-B structural region comprises a sequence substantially similar to a  
sequence selected from the group consisting of: bases 446-511 of SEQ ID NO: 1, bases 446-487  
of SEQ ID NO: 1, bases of 446-469 of SEQ ID NO: 1, and the RNA version of bases 446-2641  
of SEQ ID NO: 2.

Claim 9 (original): The GBV-B replicon of claim 3, wherein said replicon  
consists of:

said GBV-B 5' UTR;  
said selection or reporter sequence;  
said internal ribosome entry site;  
said GBV-B structural region;  
a NS2-NS5B region comprising a NS2 region substantially similar to the RNA version of bases 2642-3265 of SEQ ID NO: 2 joined to the 5' end of said NS3-NS5B region; and  
said GBV-B 3' UTR.

Claim 10 (original): The GBV-B replicon of claim 9, wherein  
said internal ribosome entry site has the sequence of 1324-1934 of SEQ ID NO 1;  
said GBV-B structural region comprises a sequence selected from the group consisting of: bases 446-511 of SEQ ID NO 1, bases 446-487 of SEQ ID NO 1, bases of 446-469 of SEQ ID NO 1, and the RNA version of bases 446-2641 of SEQ ID NO: 2;  
said NS2-NS5B is a Met-NS2-NS5B region consisting of said 5' AUG translation initiation codon, said NS2 region, and said NS3-NS5B region, wherein said NS2 region consists of the RNA version of bases 2642-3265 of SEQ ID NO: 2 and said NS3-NS5B consists of bases 1938-7709 of SEQ ID NO: 1; and  
said GBV-B 3' UTR is bases 7710-8069 of SEQ ID NO: 1.

Claim 11 (original): The GBV-B replicon of claim 10, wherein said replicon produces an infectious virion.

Claim 12 (currently amended): An expression vector comprising a promoter transcriptionally coupled to a nucleotide sequence coding the GBV-B replicon of claim 1 ~~any one of claim 1-11~~.

Claim 13 (currently amended): A GBV-B replicon made by a process comprising the steps of transfecting a cell with the replicon of ~~any one of claims 1-11~~ claim 1 and isolating said replicon.

Claim 14 (original): The GBV-B replicon of claim 13, wherein said cell is either a Huh7 cell, a Hep3B cell, is derived from a Huh7 cell, or is derived from a Hep3B cell.

Claim 15 (currently amended): A method of making a second GBV-B replicon from a first GBV-B replicon comprising the steps of:

a) transfecting a cell with said first replicon, wherein said first replicon is the replicon of claim 1 ~~any one of claims 1-11~~;

b) isolating a replicon from said transfected cell;

c) determining the nucleotide sequence of said replicon from said transfected cell;

and

d) producing said second replicon, wherein said second replicon contains the first replicon sequence with one or more alterations corresponding to said replicon from said transfected cell.

Claim 16 (original): The method of claim 15, wherein said cell is either a Huh7 cell, a Hep3B cell, is derived from a Huh7 cell, or is derived from a Hep3B cell.

Claim 17 (currently amended): A method of measuring the ability of a compound to affect GBV-B replicon activity comprising the steps of:

a) providing said compound to a cell containing the GBV-B replicon of claim 1 ~~any one of claims 1-11~~; and

b) measuring the ability of said compound to affect one or more replicon activities as a measure of the effect on GBV-B replicon activity.

Claim 18 (original): The method of claim 17, wherein said cell is a human hepatoma cell.

Claim 19 (original): The method of claim 18, wherein said said cell is either a Huh7 cell, a Hep3B cell, is derived from a Huh7 cell, or is derived from a Hep3B cell.

Claim 20 (original): A GBV-B replicon enhanced cell, wherein said cell has an maintenance and activity efficiency of at least 25% when transfected with a GBV-B replicon of SEQ ID NO: 1 by the Electroporation Method.

Claims 21-23 (cancelled):

Claim 24 (currently amended): A method of making a GBV-B replicon enhanced cell comprising the steps of:

- a) introducing and maintaining the GBV-B replicon of claim 1 ~~any one of claims 1-11~~ in a cell; and
- b) curing said cell of said GBV-B replicon to produce said replicon enhanced cell.

Claims 25 and 26 (cancelled):

Claim 27 (currently amended): A method of making a GBV-B replicon enhanced cell containing a functional GBV-B replicon comprising the steps of:

- a) introducing and maintaining a first GBV-B replicon in a cell, wherein said first replicon is the replicon of claim 1 ~~any one of claims 1-11~~;
- b) curing said cell of said first replicon to produce a cured cell; and
- c) introducing and maintaining a second GBV-B replicon into said cured cell, wherein said second GBV-B replicon may be the same or different than said first GBV-B replicon.

Claims 28-47 (cancelled).